Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28251689 | 0.87 | GDA (0.62) | GDANPC1RAB9A | |
| SCHEMBL28004978 | 0.87 | GDA (0.62) | GDA | |
| SCHEMBL28004452 | 0.86 | GDA (0.57) | GDANPC1RAB9A | |
| SCHEMBL29411658 | 0.83 | GDA (0.76) | GDA | |
| SCHEMBL28004595 | 0.83 | GDA (0.60) | GDA | |
| SCHEMBL6222949 | 0.81 | GDA (0.61) | GDA | |
| SCHEMBL5198603 | 0.81 | GDA (0.61) | GDA | |
| Hypoxanthine SCHEMBL27727730 | 0.81 | GDA (0.72) | GDA | |
| SCHEMBL1425017 | 0.80 | ADORA2A (0.52) | BRD4ADORA2ANPC1PKMMAOB | |
| SCHEMBL28251697 | 0.80 | ADORA2A (0.51) | BRD4ADORA2ANPC1PKMMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| CN-106117289-B | 2 '-O-MOE-3 '-H- thiophosphate nucleoside monomers and its synthetic method | 郑州大学 | 2019-02-12 | — | — | CN | claimed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | claimed |
| JP-58198500-A | — | — | None | — | — | JP | disclosed |
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | disclosed |
| US-20250011359-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2025-01-09 | — | — | US | disclosed |
| CN-113564168-B | Methods of preparing polynucleotides using multivalent cation salt compositions | 美国杰龙生物医药公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240150391-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORP (US) | 2024-05-09 | — | — | US | disclosed |
| CN-117412753-A | Bruton's tyrosine kinase inhibitors and methods of use thereof | 詹森药业有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117357548-A | Oligonucleotide composition and method for preparing same | 美国杰龙生物医药公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4286519-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORPORATION (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-1127749-A | Amino acid-substituted benzoylguanidines, a process for their preparation, their use as a medicament or diagnostic agent and a medicament containing them | HOECHST AG (DE) | 1996-07-31 | — | — | CN | disclosed |
| EP-0700899-A1 | Substituted benzoylguanidines, a process for their preparation, their use as drug or diagnostic agents as well as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-03-13 | — | — | EP | disclosed |
| US-5216141-A | OLIGONUCLEOTIDE ANALOGS CONTAINING SULFUR LINKAGES | BENNER, STEVEN | 1993-06-01 | — | — | US | disclosed |
| EP-0418309-A4 | OLIGONUCLEOTIDE ANALOGS CONTAINING SULFUR | — | 1993-01-07 | — | — | EP | disclosed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | disclosed |
| EP-0418309-A1 | OLIGONUCLEOTIDE ANALOGS CONTAINING SULFUR | BENNER, Steven Albert (CH) | 1991-03-27 | — | — | EP | disclosed |
| WO-1989012060-A1 | OLIGONUCLEOTIDE ANALOGS CONTAINING SULFUR | BENNER STEVEN ALBERT (CH) | 1989-12-14 | — | — | WO | disclosed |
| EP-0105486-A2 | 1-Monophosphate esters, 1,3-bisphosphate esters and cyclic phosphate esters of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine as antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1984-04-18 | — | — | EP | disclosed |
| JP-S58198500-A | RIBONUCLEOSIDE SUBSTITUTED WITH 4-METHOXYBENZYL GROUP IN THE 2'-POSITION | MITSUI TOATSU CHEM INC | 1983-11-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150391-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | RNGTT, NSUN2, POLN | GDA 725/4885BRD4 4599/4885ADORA2A 829/4885 |
| US-20250011359-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | RNGTT, NSUN2, POLN | GDA 725/4885BRD4 4599/4885ADORA2A 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.